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Background: Conventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist
of non-biological, disease-modifying antirheumatic drugs, among which methotrexate (MTX) is the most commonly
prescribed. However, there is a lack of consensus-based clinical and therapeutic recommendations for the use of
MTX in the management of patients with JIA. Therefore, the Methotrexate Advice and RecommendAtions on
Juvenile Idiopathic Arthritis (MARAJIA) Expert Meeting was convened to develop evidence-based recommendations
for the use of MTX in the treatment of JIA.
Methods: The preliminary executive committee identified a total of 9 key clinical issues according to the population,
intervention, comparator, outcome (PICO) approach, and performed an evidence-based, systematic, literature review.
During the subsequent Expert Meeting, the relevant evidence was assessed and graded, and 10 recommendations
were made.
Results: Recommendations relating to the efficacy, optimal dosing and route of administration and duration of
treatment with MTX in JIA, and to the issue of folic acid supplementation to prevent MTX side effects, use of MTX in
the treatment of chronic JIA-associated uveitis, combination treatment with biologic agents, and the use of vaccinations
in patients with JIA were developed. The selected topics were considered to represent clinically important issues facing
clinicians caring for patients with JIA. Evidence was insufficient to formulate recommendations for the use of biomarkers
predictive of treatment response.
Conclusions: These consensus recommendations provide balanced and evidence-based recommendations designed to
have broad value for physicians and healthcare clinicians involved in the clinical management of patients with JIA.
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Juvenile idiopathic arthritis (JIA) is one of the most
common chronic conditions of childhood. JIA comprises
a group of heterogeneous forms of arthritis characterized
by persistent joint inflammation lasting longer than
6 weeks and beginning before the age of 16 years and has
an unknown cause [1]. According to the classification* Correspondence: rolando.cimaz@meyer.it
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Rheumatology (ILAR), the term JIA covers seven mutually
exclusive categories with differences in their clinical pres-
entation, disease course and treatment response, namely
systemic arthritis, oligoarthritis, polyarthritis (rheumatoid
factor negative), polyarthritis (rheumatoid factor positive),
psoriatic arthritis, enthesitis-related arthritis, and undiffer-
entiated arthritis [1]. Conventional pharmacological
therapies consist of non-biological, disease-modifying an-
tirheumatic drugs (DMARD), among which methotrexate
(MTX) is the most commonly prescribed [2].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Levels of evidence [6]
Levels of evidence
1 Systematic review of all relevant
randomized clinical trials or n-of-1 trials
2 Randomized trial or observational
study with dramatic effect
3 Non-randomized controlled
cohort/follow-up study (observational)
4 Case series, case-control study,
or historically controlled study
5 Mechanism-based reasoning
(expert opinion, based on physiology,
animal or laboratory studies)
Grades of recommendation
A Consistent level 1 studies
B Consistent level 2 or 3 studies,
or extrapolations from level 1 studies
C Level 4 studies, or extrapolations
from level 2 or 3 studies
D Level 5 evidence or troubling,
inconsistent or inconclusive
studies of any level
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consensus-based clinical and therapeutic recommenda-
tions for the use of MTX in the management of patients
with JIA. Only two papers, one recently-published article
from the Spanish Society of Paediatric Rheumatology
(Sociedad Española de Reumatología Pediátrica; SERPE)
[3], and an older article by the Pediatric Immunology and
Rheumatology Division of the Centre for Child Health,
Heinrich-Heine-University, Düsseldorf, Germany [4] cur-
rently deal with this task.
Thus, the aim of our group was to develop
evidence-based recommendations for the use of MTX in
the treatment of juvenile idiopathic arthritis. To this end,
the Methotrexate Advice and RecommendAtions on Ju-
venile Idiopathic Arthritis (MARAJIA) Expert Meeting was
convened in Milan, Italy.
Methodology
Development of the research topics
Establishing recommendations requires the use of formal
methods, such as the nominal group technique (NGT),
which is based on discussions by an Expert Panel to
gather opinions and define a degree of consensus for
each statement.
A preliminary executive committee comprising Rolando
Cimaz, Giovanna Ferrara and Greta Mastrangelo was re-
sponsible for identifying key clinical issues using the PICO
(Population – Intervention – Comparator - Outcome)
system [5], with the aim of: 1) defining research questions,
and 2) developing criteria for selecting studies to be
reviewed by the Expert Panel in the development of clin-
ical and therapeutic recommendations for the manage-
ment of MTX in patients with JIA. The PICO framework
is designed to help researchers to achieve relevant and
precise questions that can be answered in a systematic
review structure, and allows improved specificity and
conceptual clarity of the clinical question by splitting the
questions into smaller manageable components which are
more straightforward to identify in the literature search
process.
The approach facilitates the identification of a precise
definition of a group of participants (Population), clear
reporting of the drug exposures (Intervention) and the
control group interventions (Comparator) under consider-
ation, and well-defined and clearly specified Outcomes of
the intervention being assessed. Finally, the type of Study
design to be included in the review should be reported.
The executive committee identified nine clinically im-
portant research topics relating to the use of MTX in JIA
using a structured PICO process. The topics covered effi-
cacy and safety, dosages, routes of administration, tapering,
and discontinuation of MTX, folic acid supplementation,
efficacy in JIA-associated uveitis, add-on therapy with
biologic drugs, biomarkers, and vaccination. The selectedtopics were considered to represent clinically important
issues facing clinicians caring for patients with JIA.
Strategy for the literature search
A systematic search using PubMed and the Cochrane
Library for human studies published in English until the
present was conducted on the 30th of November 2016.
The keywords used in the search were “juvenile idiopathic
arthritis” and “methotrexate” (“arthritis, juvenile”[MeSH
Terms] OR (“arthritis”[All Fields] AND “juvenile”[All
Fields]) OR “juvenile arthritis”[All Fields] OR (“juveni-
le”[All Fields] AND “idiopathic”[All Fields] AND “arthriti-
s”[All Fields]) OR “juvenile idiopathic arthritis”[All Fields])
AND (“methotrexate”[MeSH Terms] OR “methotrexa-
te”[All Fields]).
Study selection and data extraction
All papers found with the first search were initially se-
lected as appropriate to the intended purpose on the basis
of the title. Papers inconsistent with the main topic (for
example for disease or drug) were excluded. A second
revision and selection was made reading the abstracts of
remaining papers. Then all studies identified were read in
their full text.
Critical appraisal of identified studies
Each of the included studies was assessed for level of
evidence using Oxford criteria for evidence-based levels of
evidence [6]. The levels of evidence used in the analyses
are summarized in Table 1. Evidence levels are indicative
of quality regarding confidence and study design. In
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the clinical conclusions of the studies was combined with
the definition of the evidence levels.Consensus process
Expert panel composition
The Expert Panel participating in the MARAJIA Expert
Consensus Meeting held in Milan, Italy on the 12th of
April, 2017 to identify recommendations for the use of
MTX in the treatment of JIA consisted of Patrizia
Barone, Rolando Cimaz, Francesco La Torre, Silvana
Martino, Angelo Ravelli, Andrea Taddio, and Francesco
Zulian, under the methodological guidance of Giovanni
Pappagallo. Giovanna Ferrara and Greta Mastrangelo
were involved in formulating the PICO research topics
and drafting the recommendation statements.
All experts were pediatric rheumatologists, the majority
from tertiary centers with longstanding expertise in
pediatric rheumatic diseases.Formulation of clinical recommendations
During the meeting, the Expert Panel considered the sup-
porting research identified using the targeted literature
search and formulated specific recommendation statements
for each research topic. Ten clinical and therapeutic recom-
mendations for the management of MTX were drafted and
presented to the meeting with their supporting scientific
evidence for discussion and voting by the Expert Panel
towards reaching consensus.
The strength and relevance of the published evidence in
support of a clinical intervention or treatment approach
was evaluated, in addition taking into consideration the
personal clinical experience of the panel participants. Each
participant was required to express his or her expert opin-
ion by rating the statement according to the following
7-point scale: 1) completely disagree; 2) somewhat
disagree; 3) disagree a little; 4) neither agree nor disagree;
5) agree a little; 6) somewhat agree; 7) completely agree. A
score of 6 or 7 was defined as “In favor”, 3, 4 or 5 as
“Uncertain”, and 1 or 2 “Against”.
Through this process, all research statements achieved
acceptance, with a second round of voting not required
for any statement. One hundred percent agreement (a
unanimous score of 7 on the 7-point scale) was obtained
on 5 statements (Statements 2, 3, 4, 7 and 8) and 83%
agreement on Statements 1 and 6 (7 or 6) and Statement
5 (7 or 6 with a single score of 5 from one Advisor). The
research questions are detailed in Table 2.Research strategy and evidence selection
We obtained 843 references in our literature search.
Among these, we selected 209 relevant references, ofwhich 33 were clinical trials, 51 reviews, 1 Cochrane
meta-analysis and 124 articles of other types.
A total of 472 references were excluded because they
were judged not to be relevant, 139 because the studies
were mainly about biologic drugs and there was an insuffi-
cient focus on MTX, and 23 because they were published
in non-European languages. Six articles (2 clinical trials, 1
review, and 3 articles of other types) were subsequently
included from an updated literature search (28 February
2017). A flow diagram of the study selection process is
shown in Fig. 1.
Methotrexate in juvenile idiopathic arthritis:
Recommendations for use
A summary of the recommendations for the use of
MTX in JIA for each of the PICO research questions is
presented in Table 2.
Research question 1: Efficacy and safety of methotrexate
in juvenile idiopathic arthritis
Recommendation 1. MTX is recommended as the
first-line treatment in oligoarthritis that persists despite
nonsteroidal anti-inflammatory drugs (NSAIDs) and
intraarticular steroid (IAS) therapy, and in polyarticular
disease (Evidence Grade 1A).
MTX is also recommended in systemic arthritis with
predominant joint inflammation, without active systemic
features (Evidence Grade 4C).
Recommendation 2. Clinical and laboratory monitor-
ing of MTX toxicity is recommended every 4–8 weeks
initially, and then every 12–16 weeks, unless risk factors
are present (Evidence Grade 4C).
PICO framework: P: children affected by JIA; I: admin-
istration of MTX; C: placebo or other therapies (salazo-
pyrin, oral steroids, NSAIDs); O: efficacy and safety.
MTX is the most widely used DMARD in the treatment
of JIA. A folic acid analog and an inhibitor of several
different enzymes in the folate pathway, MTX exerts
immunomodulatory and anti-inflammatory actions. Its
efficacy was first demonstrated in a randomized controlled
trial more than two decades ago [7]. MTX has been
studied in further controlled clinical trials [8, 9] and has
been established as the most common first-line DMARD
treatment according to several national treatment guide-
lines [10–13]. In particular, considering the categories of
JIA, NSAIDs and IAS therapy remain the first choice in
oligoarthritis [1]. Furthermore, a recent multicenter,
prospective, randomized, open-label trial [14] found that
concomitant administration of MTX did not augment the
effectiveness of intra-articular corticosteroid therapy.
MTX is recommended as first-line treatment in polyar-
thritis, and in systemic arthritis with predominant joint
inflammation [2, 8, 11, 15]. However, initiation of sulfasala-
zine (SSZ) is recommended following IAS or an adequate
Table 2 Summary of recommendations for the use of methotrexate in juvenile idiopathic arthritis




Research question 1: Efficacy and safety of methotrexate in juvenile idiopathic arthritis
1. MTX is recommended as the first-line treatment in oligoarthritis that persists despite
nonsteroidal anti-inflammatory drugs (NSAIDs) and intraarticular steroid (IAS) therapy,
and in polyarticular disease
1A [2–4, 7–15, 20, 21, 23–25]
MTX is also recommended in systemic arthritis with predominant joint inflammation,
without active systemic features
4C [2–4, 7–15, 20–25]
2. Clinical and laboratory monitoring of MTX toxicity is recommended every 4-8 weeks
initially, and then every 12-16 weeks, unless risk factors are present
4C [1, 4, 12, 21, 26–38, 40–42]
Research question 2: Dosages of methotrexate in juvenile idiopathic arthritis
3. A dose of 10-15 mg/m2/week is recommended. 5D [7, 9, 42]
Further increases in MTX dosage have not been associated with additional therapeutic benefit 1A
Research question 3: Route of administration of methotrexate in juvenile idiopathic arthritis
4. MTX may be given orally or subcutaneously once a week. If high doses (15 mg/m2/week)
are requested, the subcutaneous route is preferable due to increased bioavailability
4C [9, 21, 43–49]
Research question 4: Tapering and discontinuation of methotrexate in juvenile idiopathic arthritis
5. MTX could be discontinued after 6 months of stable remission 1A [50–52]
Research question 5: Folic acid supplementation for the prevention of methotrexate toxicity in patients with juvenile idiopathic arthritis
6. Folic or folinic acid supplementation is recommended to prevent MTX side effects. 1A [53–57, 59–62]
The advised dose is approximately one third of the MTX dose, at least 24 hours after
the weekly dose of MTX for folinic acid; for folic acid 1 mg/day skipping the day when
MTX is administered
4C
Research question 6: Efficacy of methotrexate in uveitis associated with juvenile idiopathic arthritis
7. MTX is recommended for the treatment of JIA-related uveitis refractory to topical treatment 4C [63–72, 74–79]
Research question 7: Add-on therapy with biologic drugs in juvenile idiopathic arthritis not responding to methotrexate
8. The combination of MTX with a TNF-α inhibitor is recommended in patients who had
an inadequate clinical response to MTX alone
3B [11, 48, 80, 83–85, 88, 89]
Combination therapy is safe and may reduce the development of anti-drug antibodies 2B [83, 88–90]
Research question 8: Molecular elements and genetic markers of response to methotrexate in juvenile idiopathic arthritis – Biomarkers
9. No recommendation is made regarding the use of biomarkers in current clinical practice [91–101]
Research question 9: Use of vaccination in patients with juvenile idiopathic arthritis treated with methotrexate
10. Vaccination with non-live vaccines is not contraindicated during MTX treatment 2B [101–119]
No recommendation can be formulated for live-attenuated vaccines, but the available data
for measles, mumps, rubella (MMR) booster indicate that it is safe and adequately immunogenic
Abbreviations: IAS intra-articular steroid, JIA juvenile idiopathic arthritis, MMR measles, mumps, rubella, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory
drugs, TNF-α tumor necrosis factor-α
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ritis category of JIA, with moderate activity [11]. Sulfasala-
zine has never been compared with MTX in treating JIA.
Currently, there are no published recommendations for
the treatment of juvenile spondyloarthropathies. The ACR
recommendations for the management of JIA suggest the
use of sulfasalazine for patients with enthesitis-related
arthritis. This recommendation is based on clinical
experience and data from adult patients with ankylosing
spondylitis. However, in the adult population it has been
shown that sulfasalazine is ineffective in axial disease,
while several observational studies have found that tumor
necrosis factor (TNF)-α inhibitors are beneficial in
juvenile spondyloarthropathies [16–19]. Furthermore,a recent randomized controlled trial demonstrated the
efficacy of adalimumab in enthesitis-related arthritis
[16, 18]. Available studies suggest that TNF-α inhibitors
should be used when sulfasalazine is ineffective or earlier in
moderate or highly active axial disease with established
radiographic damage, such as erosions or joint-space
narrowing.
MTX has been shown to be an effective drug in the in-
dication, with 65–90% of patients successfully responding
to treatment [9, 20–22]. MTX also significantly improved
a wide range of health-related quality-of-life components,
particularly in the physical domains [23].
Despite what has previously been reported in adult
patients, MTX may also slow the radiologic progression of
Fig. 1 Study selection process flow diagram
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the studies available involved few children [24, 25].
During 30 years of its use, MTX has shown a good
safety profile, with few severe side effects reported [26].
Nevertheless, more than half of children were reported to
have difficulties in taking it [27, 28]. The most common
side effect of MTX include nausea or vomiting and abnor-
malities in liver function tests, the latest reported in 10–
20% of patients [29, 30]. However, the transaminase levels
usually normalize one or two weeks after stopping
therapy. Others symptoms are mouth sores, rash, diarrhea
and laboratory abnormalities such as leukopenia and
hypogammaglobulinemia that may predispose to infec-
tions. Alopecia is seen in some patients, but hair grows
back after stopping the medication. Since photosensitivity
has been reported, limiting sun exposure and the use of
sunscreen is advised. It is worth remembering that MTX
is teratogenic, and it is necessary to use contraception
while taking the drug and for 3–6 months after discon-
tinuation [29].
MTX may cause cirrhosis and lung fibrosis, but these are
extremely rare and have been reported only in adults with
other comorbidities [31–33]. In the literature there are also
few reports of lymphoma in children treated with MTX
[34–36], but it has not been possible to determine whether
these observations were merely coincidental, were causally
linked to MTX, or were related to the underlying disease
process. The issue of whether MTX treatment is an inde-
pendent risk factor for various malignancies is controver-
sial and remains unresolved. Long-term prospective cohort
studies are needed to define the risk of hematological or
other malignancies in MTX-treated patients.
Nodulosis is a rare MTX adverse event that has been
described in JIA (accelerated nodulosis in two teenagerswith rheumatoid factor [RF]-positive juvenile rheuma-
toid arthritis and one 3-year-old girl with systemic-onset
disease). The nodules developed within six months after
the initiation of MTX treatment and regressed after
discontinuing therapy, or were successfully treated with
hydroxychloroquine or colchicine [37–39].
Regarding laboratory monitoring in patients with JIA,
there is only one guideline by Ortiz-Alvarez et al., derived
from the American College of Rheumatology (ACR)
guidelines for monitoring MTX toxicity in adults. They
suggest a complete and differential blood count, liver
function tests and albumin and serum creatinine levels
every 4–8 week initially, and then every 12–16 week,
unless risk factors are present [40]. Other authors also
recommended hepatitis and varicella-zoster virus ser-
ology and tuberculin test before starting therapy [4].
MTX is contraindicated in children with reduced renal
function.
Bulatović et al. [27] designed and validated the MTX In-
tolerance Severity Score (MISS) questionnaire to identify
patients with MTX intolerance. The items investigated
were: abdominal signs and symptoms (pain, nausea, vomit-
ing) and behavioral symptoms (restless, crying, irritability,
and refusal of MTX) before and after the administration
of MTX. A cut-off score of 6 yielded the best sensitivity
(88%) and specificity (80%). They found there was no
difference in efficacy between the various routes of MTX
administration. However, half of the 297 patients were
MTX-intolerant. This was especially the case in patients
who received parenteral MTX, who experienced more
anticipatory behavioral symptoms prior to administration,
compared to patients receiving oral MTX. However, the
difference in the prevalence of gastrointestinal symptoms
was not great.
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among patients who received parenteral MTX. On the other
hand, Klein et al. [21] found no difference in the prevalence
of side effects between oral and parenteral MTX.
Overall, analysis of available studies and clinical
experience of the participating experts show that MTX
is usually well tolerated in patients with JIA.Research question 2: Dosages of methotrexate in juvenile
idiopathic arthritis
Recommendation 3. A dose of 10–15 mg/m2/week is
recommended (Evidence Grade 5D). Further increases in
MTX dosage have not been associated with additional
therapeutic benefit (Evidence Grade 1A).
PICO framework: P: children affected by JIA on treat-
ment with MTX; I: low dosage of MTX (< 10 mg/m2/
week); C: high dosage of MTX (> 10 mg/m2/week); O:
efficacy and safety.
The therapeutic range of MTX for JIA is 8.5–15 mg/
m2/week. The first study by Giannini et al. showed that a
dose of 5 mg/m2/week was not superior to placebo, while
15 mg/m2/week was superior to 10 mg/m2/week [7].
Children seem to tolerate much higher doses than
adults, and some series have described using 20 to 25 mg/
m2/week or 1.1 mg/kg/week in children with resistant dis-
ease with relative safety in the short-term [42]. However, a
multinational, randomized controlled study confirmed this
therapeutic range and showed no benefit of doses above
15 mg/m2/week [9].Research question 3: Route of administration of
methotrexate in juvenile idiopathic arthritis
Recommendation 4. MTX may be given orally or sub-
cutaneously once a week. If high doses (15 mg/m2/week)
are requested, the subcutaneous route is preferable due
to increased bioavailability (Evidence Grade 4C).
PICO framework: P: children affected by JIA on treat-
ment with MTX; I: subcutaneous administration of MTX;
C: oral administration of MTX; O: efficacy, safety, and
tolerability.
There is significant intraindividual and interindividual
variability in the absorption and pharmacokinetics of
MTX after oral administration [43, 44].
A pharmacokinetic study showed that factors such as
age, body weight, creatinine clearance, gender, dose, and
fasting state significantly influenced the absorption of
MTX in adults with rheumatoid arthritis. The bioavail-
ability of MTX has also been shown to be greater in the
fasting state in children with JIA [45].
MTX should be taken on an empty stomach with
water or clear beverages. Oral bioavailability generally is
about 15% less than after intramuscular administration.
The bioavailability of intramuscular and subcutaneousadministration is similar, with the latter being generally
more acceptable for children who require parenteral
MTX [46, 47].
Several studies have reported the successful use of paren-
teral treatment in non-responders to oral MTX treatment,
but there are no controlled comparative studies (only
open-label studies are available). Alsufyani et al. found that
patients switching from oral to subcutaneous administra-
tion of MTX had a 70% improvement in response [48].
Klein et al. in a retrospective study showed no differ-
ences in effectiveness between oral and parenteral admin-
istration of MTX, even if more patients on parenteral
therapy discontinued it [21]. In clinical practice, MTX is
preferentially administrated subcutaneously, and there is
no sound study demonstrating greater efficacy for the oral
route of MTX administration.
At doses over 15 mg/m2/week, the parenteral route may
be better because of the decreased oral bioavailability of
the drug at high doses. It has been shown that subcutane-
ous administration of MTX has a 10–12% increased
absorption compared with oral preparations [46, 49]. In
discussion amongst the Panel members, it was noted that
in clinical practice, treatment is usually started with MTX
15 mg/m2/week, particularly in severe forms of JIA, where
the patient is directly treated with MTX 15 mg/m2/week.
The Panel further suggested that, for the first administra-
tions, the starting dose can be 10 mg/m2/week, and then
the dose can be increased at subsequent MTX administra-
tions, if necessary. Ruperto et al. reported that MTX doses
greater than 15 mg/m2/week provided no additional clin-
ical benefit, and that this dose should not be exceeded [9].
Research question 4: Tapering and discontinuation of
methotrexate in juvenile idiopathic arthritis
Recommendation 5. MTX could be discontinued after
6 months of stable remission (Evidence Grade 1A).
PICO framework: P: children affected by JIA on treat-
ment with MTX; I: tapering and discontinuing treatment
six months after achieving remission; C: discontinuing
MTX twelve months or longer after achieving remission;
O: survival free of flares after stopping treatment.
MTX is a slow-acting drug, generally displaying its full
therapeutic effect in 6–8 weeks (from 3 to 18 weeks
among different studies), so there is general agreement
to wait at least 12 weeks to assess its efficacy. On the
contrary, there is a wide variability on the tapering and
discontinuation of MTX doses in everyday clinical
practice. There have been many studies in children
treated with variable doses of MTX for variable periods
in whom discontinuation of MTX was attempted after
clinical “remission” of variable length was achieved [50].
The criteria for “remission” or “relapse” have usually not
been well defined or standardized among various studies,
and the assessment of outcomes has been nonblinded.
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safety of withdrawing MTX therapy after 6 months of
stable remission versus 12 months. The results of this
study that included 364 patients showed that a 12-month
versus 6-month withdrawal of MTX did not reduce the re-
lapse rate [51].
MTX withdrawal may result in disease flare in more
than 50% of patients, and even more in younger children.
A longer period on MTX treatment after remission may
not prolong the duration of improvement after stopping
treatment, but the duration of clinical remission may be
predicted by the degree of subclinical synovial inflamma-
tion (using myeloid related proteins 8 and 14 [MRP8/
MRP14]) at the time of stopping MTX [52].
Research question 5: Folic acid supplementation for the
prevention of methotrexate toxicity in patients with
juvenile idiopathic arthritis
Recommendation 6. Folic or folinic acid supplementa-
tion is recommended to prevent MTX side effects (Evi-
dence Grade 1A). The advised dose is approximately one
third of the MTX dose, at least 24 h after the weekly dose
of MTX for folinic acid; for folic acid 1 mg/day skipping
the day when MTX is administered (Evidence Grade 4C).
PICO framework: P: children affected by JIA on treat-
ment with MTX; I: MTX and folic acid supplementation;
C: MTX alone; O: frequency (prevalence/incidence) of
nausea and dyspepsia.
MTX toxicity, such as hepatotoxicity, hematologic
changes, gastrointestinal and mucocutaneous intoler-
ance, has been hypothesized to be a result of an induced
state of folate depletion. The addition of folate, there-
fore, can counteract the signs of toxicity, either as folic
or folinic acid (a reduced form of folic acid), since they
can function in biosynthetic pathways independent of
dihydrofolate reductase.
In a double-blind placebo-controlled study in RA, 1–
5 mg of folic acid led to a significant reduction of side ef-
fects whilst preserving the efficacy of MTX therapy, even if,
in order to preserve the anti-inflammatory effect, a slightly
higher dosage of MTX was necessary [53]. Several clinical
studies showed also that folic acid supplementation is asso-
ciated with a reduced MTX discontinuation rate [53–55].
According to available data, folic acid supplementation
does not appear to interfere with the therapeutic
efficacy of MTX [55–57]. Indeed, there is increasing
evidence that the anti-inflammatory effect of MTX is
mediated by adenosine and is unrelated to folic or
folinic acid [58]. A randomized controlled study, which
directly compared folic acid to folinic acid in rheuma-
toid arthritis, showed no difference between the two
forms of supplementation [53].
Studies in children are limited. A 13-week, randomized,
double-blind, placebo-controlled, crossover trial of folicacid (1 mg/day) or placebo combined with a stable dose of
MTX in 19 children with juvenile rheumatoid arthritis
reported no effect on the clinical efficacy of oral weekly
MTX. No liver function tests abnormalities were observed,
but no data about other toxicities were available [59]. Ac-
cording to the findings of the studies conducted in adults,
the frequency of increased transaminases is reduced by 60%
by folinic acid supplementation [57]. Furthermore, in a
retrospective non-controlled study [60] the efficacy of
folinic acid supplementation was investigated in a cohort of
43 children on an intermediate dose of MTX. A significant
reduction in hepatotoxicity and gastrointestinal toxicity was
shown, without compromising MTX efficacy.
Administration of folic or folinic acid 24 h apart from
the administration of MTX, in a dose of approximately
one-third of the MTX dose, has been used to prevent
MTX toxicity manifestations [61].
However, in limited cases, it is reported that at high
doses folic acid supplementation seems to be associated
with disease flares [62].
According to available data, it is not possible to make
firm recommendations about routine folate supplementa-
tion in children receiving MTX treatment. However, data
from adult studies and limited pediatric data can provide
helpful information. Low-dose (1 mg/day) folic acid supple-
mentation does not affect the anti-inflammatory efficacy of
MTX and counteracts the signs of gastrointestinal and
mucosal toxicities associated with it. The advisable dose is
approximately one-third of the MTX dose, at least 24 h
after the weekly dose of MTX, or 1 mg/day skipping the
day when MTX is administered (Grade 4C). Folic acid
supplementation does not appear to interfere with the
therapeutic efficacy of MTX and seems to be associated
with a reduced MTX discontinuation rate.
Research question 6: Efficacy of methotrexate in uveitis
associated with juvenile idiopathic arthritis
Recommendation 7. MTX is recommended for the
treatment of JIA-related uveitis refractory to topical
treatment (Evidence Grade 4C).
PICO framework: P: children affected by JIA and uveitis;
I: administration of MTX; C: placebo or other therapies
(e.g., oral steroids); O: efficacy and safety.
Although there is a lack of randomized controlled
studies on the subject, the available data suggest that
MTX is useful for preventing the onset of uveitis and
improving disease activity in cases of JIA. In particular, a
systematic review and meta-analysis of prospective stud-
ies carried out by Simonini et al. found that there was a
73% (95% confidence interval 66–81%) likelihood of im-
proving intraocular inflammation in patients treated
with MTX [63]. The systematic review was based on
data from nine retrospective chart reviews [63–72]. The
number of children in studies varied from 3 to 25, and
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15 mg/m2 the most commonly used. Ninety-five of 135
children were responders to MTX. The outcome mea-
sures to assess the effectiveness of MTX were collected
according to the Standardization of Uveitis Nomencla-
ture working group criteria [73]. It was reported that
additional topical steroids or systemic immunosuppres-
sive drugs were often required. However, the lack of ran-
domized controlled trials means that treatment with
immunosuppressive drugs is supported only at evidence
level III: expert opinion, clinical experience or descrip-
tive studies [74].
Additionally, Charuvanij and colleagues [75] reviewed
the medication history in 43 children with JIA and
anterior uveitis. Topical corticosteroids alone permitted
satisfactory disease control in few patients (16%). The
addition of MTX controlled the uveitis in three-quarters
of patients, but additional systemic immunosuppressive
drug (infliximab) was required in 6 children, with disease
control in 4 patients.
The lack of evidence from randomized controlled trials
limits our understanding of MTX effectiveness in the in-
dication and of the best time to start therapy, even
though MTX is largely used in chronic uveitis, mostly
when associated with JIA.
Heiligenhaus et al. [76] suggest adding an immunosop-
pressive drug (i.e. MTX) to steroids when the inflamma-
tion in the eyes has not resolved within 12 weeks under
treatment with topical corticosteroids maximally 3 times
daily or, in cases of recurring uveitis, under a systemic
corticosteroid dosage of more than 0.15 mg/kg body
weight or if new uveitis complications develop. The pre-
ferred dose is 15 mg/m2/week (maximum 25 mg/m2/
week) [77]. Evidence from several sources suggested that
if MTX is effective in controlling inflammation, treat-
ment should be maintained for 12 months from when
inactive uveitis has been confirmed. In patients with
poor visual prognosis, MTX treatment should be main-
tained over 24 months [77].
In terms of preventing the onset of uveitis in children
during early treatment with MTX Papadopoulou et al.
[78] performed a retrospective study of 254 patients with
JIA. Eighty-six patients (33.9%) were treated with MTX
and 168 patients (66.1%) did not receive MTX. Over the
2-year follow-up, the frequency of uveitis was lower in
patients who had received MTX than in untreated
patients (10.5% vs 20.2%, respectively, p = 0.049). The ma-
jority of patients in the study had persistent and extended
oligoarthritis (61.8 and 22.4%, respectively); 14.2% of pa-
tients had RF-negative polyarthritis. As expected, patients
treated with MTX had a greater frequency of polyarticular
disease, which is well known to have a lower incidence of
uveitis. However, the distribution of the main risk factors
for uveitis (proportion of female and antinuclearantibodies- positive subjects) and the median age at dis-
ease onset were comparable between the two groups. In a
longitudinal analysis from a nationwide pediatric rheuma-
tology database [79] the influence of MTX, TNF-α inhibi-
tors, and a combination of the 2 medications on uveitis
occurrence in JIA patients was analyzed. In a total of 3512
patients the use of any of these drugs in the year before
uveitis onset significantly reduced the risk for uveitis, and
the use of MTX within the first year of disease and of the
combination of MTX with a TNF-α inhibitor had the
highest protective effect.
In a recent systematic review [63], MTX seems an
effective therapy for uveitis associated with JIA.
Research question 7: Add-on therapy with biologic drugs
in patients with juvenile idiopathic arthritis not
responding to methotrexate
Recommendation 8. The combination of MTX with a
TNF-α inhibitor is recommended in patients who had an
inadequate clinical response to MTX alone (Evidence Grade
3B). Combination therapy is safe and may reduce the devel-
opment of anti-drug antibodies (Evidence Grade 2B).
PICO framework: P: children affected by JIA on treat-
ment with MTX who did not achieve remission; I: MTX
plus TNF-α inhibitors (etanercept and adalimumab); C:
MTX alone; O: efficacy and safety.
The ACR recommendations [11] propose the addition
of a TNF-α inhibitor (etanercept or adalimumab) for
patients who had a partial previous clinical response to
MTX with persistent disease activity, recommending,
after starting combination therapy, that treatment with
MTX be continued or not depending on the patient’s
previous response to it.
Two retrospective cohort studies recommended com-
pletion of a maximal response timeframe and to achieve
the maximum effective dose by the parenteral route
before considering combination therapy [48, 80].
Studies in adult patients with RA revealed a superior-
ity of combining MTX and etanercept versus MTX only
[81, 82]. This combination has also been successfully
used in children and adolescents, despite a lack of
double-blind, randomized controlled trials [83].
A 3-year, open-label, prospective multicenter study of
children and adolescents (aged 2–18 years) with polyar-
ticular, systemic, or extended oligoarticular JIA receiving
MTX (n = 197), etanercept (n = 103), or both (n = 294)
showed good safety and efficacy in all three groups. The
results of this study indicated that patients with polyarti-
cular (RF-positive or negative) or systemic JIA benefit
from etanercept or etanercept plus MTX treatment [84].
Improvements in joint counts and physician’s global as-
sessment scores were similar across three different arms,
and improvements were maintained for three years in
those continuing to receive medication.
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placebo-controlled, multicenter, medication-withdrawal
study with a 16-week open-label lead-in phase, a 32-week
double-blind withdrawal phase, and an open-label exten-
sion phase, 171 children with active juvenile rheumatoid
arthritis underwent stratification according to MTX use
(85 patients receiving MTX, 86 not receiving MTX) and
received adalimumab every other week for 16 weeks.
Subsequently, those that had an ACR Pediatric 30%
(ACR Pedi 30) response at week 16 (74% of patients not
receiving MTX and 94% of those receiving MTX) were
randomly assigned to receive adalimumab or placebo in a
double-blind fashion every other week for up to 32 weeks.
At 48 weeks, the percentages of patients treated with
MTX who had ACR Pedi 30, 50, 70, or 90 responses were
significantly greater for those receiving adalimumab than
for those receiving placebo; the differences between pa-
tients not treated with MTX who received adalimumab
and those who received placebo were not significant.
The study was not statistically powered to detect
differences between patients receiving and those not
receiving MTX; however, the proportions of patients
with ACR Pedi 30, 50, 70, or 90 responses were
somewhat higher among those receiving adalimumab
in combination with MTX than among those receiv-
ing adalimumab without MTX [85].
A diminished response to treatment with certain TNF-α
inhibitors may be associated with the development of
anti-drug antibodies [86], and concomitant use of MTX
reduces the immunogenicity of these drugs [85, 87].
Concerning safety, several studies reported that
MTX combined with anti-TNF-α does not increase its
toxicity [83, 88–90].
MTX in combination with biologic therapy is safe
and may reduce the development of anti-drug anti-
bodies in addition to improving response.
Research question 8: Molecular elements and genetic
markers of response to methotrexate in juvenile
idiopathic arthritis – Biomarkers
Recommendation 9. No recommendation is made re-
garding the use of biomarkers in current clinical practice.
PICO framework: P: children affected by JIA undergoing
treatment with MTX; I: evaluating the concentration of
MTX polyglutamates and genetics variants in MTX
responders; C: polyglutamate levels and genetic variants in
patients with JIA non-responders to MTX; O: response to
MTX in children with JIA.
Although MTX is the first choice in JIA, it is known
that about one-third of patients fail to respond. Given
the time lag between MTX treatment initiation and the
patient response (about 3 months), it would be particu-
larly useful to determine a priori the probability of bene-
ficial therapeutic response [91, 92].In fact, the delay in identifying the optimal treatment at
an early stage of disease can influence long-term joint
damage. Several biomarkers have been investigated so far.
Recent studies found that the effect of MTX in JIA is asso-
ciated with MTX polyglutamate intracellular concentra-
tions: elevated long chain MTX polyglutamate levels are
associated with lower disease activity indexes (JADAS)
during 1 year of MTX treatment in JIA [93–95].
Other studies have evaluated the effects of genetic variants
in the complex pathway of candidate genes involved in
MTX pharmacokinetics and pharmacodynamics on the re-
sponse to the medication in children with JIA. These studies
found that genetic variants that predict MTX response in
JIA are those in 5-aminoimidazole-4-carboxamide
ribonucleotide-transformylase (ATIC), inosine triphosphate-
pyrophosphatase (ITPA) and SLC19A1 genes [96–99].
Pastore et al. showed that reduced activity of ITPA, an
enzyme involved in nucleotides’ homeostasis, is related to
reduced MTX efficacy in patients with JIA [100]. The same
group also found that a common functional variant in
ATIC gene is associated with good response to MTX, while
a variant in ITPA is associated with reduced response to
MTX. However, there are suggestions that genetic variabil-
ity, specifically single-nucleotide polymorphisms (SNP), in
MTX metabolic pathways may be a better marker for MTX
toxicity than for efficacy [99].
The conclusions of these studies may suggest that
patients with variants associated with lack of efficacy for
MTX should be switched more rapidly to a more aggressive
treatment, but studies specifically addressing this issue are
still lacking. In the future, therapy personalization in JIA
may be achieved by a pharmacological approach integrating
pharmacokinetic and pharmacogenomic evaluations. How-
ever, the supporting evidence is not yet sufficiently robust
to form the basis of a recommendation.
Therefore, it was determined that the place of pharmaco-
kinetic and pharmacogenomic analysis performed before
MTX treatment in patients with JIA to identify those
predisposed to better responses currently undefined and,
furthermore, in current clinical practice no assessment of
the biomarkers predictive of treatment response is carried
out. Therefore, it was decided that no recommendation
regarding the use of biomarkers in the treatment of patients
with JIA should be made.
Research question 9: Use of vaccination in patients with
juvenile idiopathic arthritis treated with methotrexate
Recommendation 10. Vaccination with non-live vaccines
is not contraindicated during MTX treatment (Evidence
Grade 2B).
No recommendation can be formulated for live-attenuated
vaccines, but the available data for measles, mumps, rubella
(MMR) booster indicate that it is safe and adequately
immunogenic.
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ment with MTX; I: vaccinations during treatment with
MTX; C: no vaccinations during treatment with MTX;
O: safety and efficacy of vaccinations, safety of drugs.
Considering that children with JIA have an increased
risk of infection, which contributes to the morbidity of
their disease, non-live vaccines, and live-attenuated vac-
cines can be recommended in these patients. However,
the presence of immunosuppressive drugs can interfere
with effectiveness and safety of vaccinations.
In 2011, the European League Against Rheumatism
(EULAR) published recommendations regarding the vac-
cination of children with rheumatic diseases [101], based
on a systematic literature review published in that same
year [102]. The EULAR guidelines recommend adher-
ence to the national vaccination guidelines for
live-attenuated vaccines in pediatric patients unless the
patients are on high-dose immunosuppressants,
high-dose cortisone or biological agents. Booster vacci-
nations against varicella, yellow fever, and measles,
mumps, rubella (MMR) can be considered in patients
receiving MTX less than15mg/m2 or low-dose cortico-
steroids. However, it should be noted that the MTX
summary of product characteristics states that live vac-
cines are contraindicated in patients taking MTX.
Recently Groot et colleagues provided an update to July
2014 of the systematic literature study of 2011 [103]. Eight
studies on MTX and vaccinations, counting in total 420
patients, were available in the Groot review concerning
the most common vaccines, i.e., seasonal influenza virus
and H1N1, hepatitis B virus (HBV), meningococcus C,
pneumococcus, measles, mumps and rubella (MMR), vari-
cella zoster virus (VZV), bacillus Calmette-Guérin (BCG)
[104–111]. Further we found five more articles about the
above-mentioned vaccines including subgroups of patients
on MTX [112–116], and one more concerning the
bivalent human papillomavirus (HPV) vaccine [117].
In a prospective controlled observational cohort study,
the immunogenicity of the bivalent HPV 16/18 vaccine in
68 patients with JIA was compared to 55 healthy controls,
showing that all participants were seropositive up to
12 months after vaccination. No deleterious effect of
MTX on antibodies was detected in the subgroup of 24
patients on MTX. No relevant differences in adverse
events were found, and HPV vaccination did not aggravate
JIA disease activity [117].
In two prospective open-label studies, influenza vaccine
response and safety among patients treated with MTX
were compared with a control group. Both studies showed
that influenza vaccination in JIA induces a lower but
effective protective antibody response with an adequate
disease safety profile [109, 111].
Kasapcopur et al. compared responsiveness and safety
of hepatitis B vaccination in 39 children affected by JIAand 41 healthy children. No effect of MTX on antibody
concentration or response rate and no increase in disease
activity were observed. A vaccination schedule at 0, 1,
6 months appeared to be the most effective [105].
The Neisseria meningitidis C (NeisVac-C) vaccine, is
also safe and immunogenic in patients with JIA [115]. A
retrospective cohort study showed that persistence of
MenC-specific immunoglobulin (Ig)G antibodies in
patients with JIA is similar to healthy controls and there is
no effect of MTX on the decline of antibody levels over
time, unlike biologicals [107].
Farmaki and colleagues observed that patients with
JIA, when using MTX, had a similar response and sero-
protection rate to the 7-valent pneumococcal vaccine
(PCV7) as in healthy controls [114]. The only study
evaluating the 23-valent polysaccharide pneumococcal
vaccine in patients with JIA also demonstrated vaccine
safety and effectiveness [116].
In a randomized, multicenter, open-label clinical
equivalence trial, 137 patients with JIA aged 4 to 9 years
(60 using MTX and 15 using biologics) were randomly
assigned to receive MMR booster vaccination (n = 68) or
no vaccination (control group; n = 69). Disease activity
during complete follow-up did not differ between revac-
cinated patients and controls and seroprotection rates at
12 months after vaccination were higher in revaccinated
patients. It seems that MTX and biologics did not affect
humoral responses, but low patient numbers precluded
definite conclusions. Moreover, no disease due to infec-
tions with attenuated viruses occurred in patients treated
with immunosuppressive drugs [113]. A retrospective
cross-sectional study [104], a retrospective observational
multicenter cohort study [108] and a prospective
case-control study [110] confirm these results.
In a prospective study [112], safety and immunogenicity
of the VZV vaccine among 25 patients with pediatric
rheumatic diseases treated with MTX and corticosteroids
were compared to 18 healthy children. The vaccine
proved to be safe in MTX treated patients, and no severe
treatment-related adverse effects were observed during
the one year follow up period. Both patients and controls
had a low seroconversion rate one year after vaccination.
However, a recent study [118] showed a low seroconver-
sion rate in susceptible healthy children after one dose of
vaccine, and indeed the US Centers for Disease Control
and Prevention (CDC) guidelines advocate the use of 2
doses [119]. In clinical practice, a booster dose of VZV
vaccine is normally administered to patients who fail to
exhibit an immunological response after the first dose.
Kiray et al. demonstrated that there is no effect of MTX
on purified protein derivative (PPD) induration size several
years after BCG vaccination [106]. The PPD positivity rate
was similar in MTX users and nonusers, even if the re-
sponse to PPD was significantly lower in BCG-vaccinated
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because of the lack of safety data, BCG vaccinations should
not be administered to patients on immunosuppressive
drugs (including MTX) or biologicals.
According to available data, no detrimental effect of MTX
on the short-term immunogenicity or on the persistence of
antibodies over time and no relevant increase in
vaccine-associated adverse events were found in patients
treated with MTX. Non-live vaccines are generally ad-
equately immunogenic and safe. It appears that
live-attenuated vaccines can be safely and effectively
administered to patients with JIA on MTX, unless they are
also on additional immunosuppressive drugs or biologicals.
In these cases, evidence on safety is scarce. Live-attenuated
booster vaccinations can be considered on an individual
basis, although the data do not currently support the formu-
lation of a specific recommendation for live-attenuated vac-
cines. There is no evidence in pediatric patients about the
safe time intervals for the administration of live vaccines
after cessation of immunosuppressive/immunomodulatory
drugs such as MTX.
Discussion
Although MTX is accepted as the most effective
non-biologic agent for the treatment of patients with JIA,
there is a wide variability in everyday practice in the use of
MTX in the management of JIA. Therefore, the adoption
of a consensus approach by a group of practitioners expert
in the use of the drug in treating patients with JIA has the
potential to guide clinicians and improve the understand-
ing and management of this condition.
The recommendations presented in these consensus
guidelines developed by the panel of experts participating
in the MARAJIA Expert Consensus Meeting are based on
a high level of evidence provided in large measure by ro-
bust data from randomized controlled clinical trials. Based
on a set of key clinical issues developed using the PICO
system and a rigorous approach to evidence review and
the formulation of the research questions adopted to
reduce the introduction of biases and to ensure balanced
and evidence-based recommendations, we identified
sound scientific support to guide the use of MTX in
patients with JIA. Our consensus-based analysis integrated
the scientific evidence from the literature with clinical
experience to provide a set of recommendations we
believe are of value in helping clinicians optimize the
treatment of their patients with a diagnosis of JIA.
Conclusions
These consensus recommendations relating to the
efficacy, optimal dosing and route of administration and
duration of treatment with MTX in JIA, and to the
important issues of folic acid supplementation to prevent
MTX side effects, use of MTX in the treatment of chronicJIA-associated uveitis, combination treatment with
biologic agents, and the use of vaccinations in patients
with JIA provide balanced and evidence-based recommen-
dations designed to have broad value for physicians and
healthcare clinicians. We did not at this time find suffi-
cient evidence to justify pharmacokinetic and pharmaco-
genomic analysis prior to MTX treatment in current
clinical practice, as insufficient evidence is available on
biomarkers able to predict treatment response.
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